Advertisement

Drug-eluting Stents

  • Anoop Chauhan
  • Ranjit S. More
Chapter

Abstract

Over the last decade, the most radical change in percutaneous coronary intervention (PCI) practice has been the rapid incorporation of intracoronary stenting, to the extent that it is now used in well over 80% of all angioplasty procedures. This change in practice has occurred as a consequence of landmark studies, such as STRESS (Stent Restenosis Study) and BENESTENT (Belgian Netherlands Stent) [1, la]. These studies demonstrated conclusively that stenting could reduce restenosis after coronary intervention. Nevertheless, significant rates of in-stent restenosis, on the order of 20% to 30% (angiographic restenosis), still occur, presenting a challenging problem [2].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Serruys PW, Jaegere PD, Kiemenij F, et al.: A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994, 331:489–495.PubMedCrossRefGoogle Scholar
  2. 1a.
    Fischman DL, Leon MB, Bairn DS, et al.: A randomized comparison of coro-nary-stent placement and balloon angioplasty in the treatment of coronary disease. N Engl J Med 1994, 331:496–501.PubMedCrossRefGoogle Scholar
  3. 2.
    Mintz GS, Hoffmann R, Mehran R, et al.: In-stent restenosis: the Washington Hospital Center experience. Am J Cardiol 1998, 81:7E–13E.CrossRefGoogle Scholar
  4. 3.
    Topol EJ, Faxon DP: Symposium on restenosis: from basic studies to clinical trials. J Am Coll Cardiol 1991, 17:1B–194B.CrossRefGoogle Scholar
  5. 4.
    Mintz GS, Popma JJ, Pichard AD, et al.: Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularisation. J Am Coll Cardiol 1996, 27:1678–1687.PubMedCrossRefGoogle Scholar
  6. 5.
    Virmani R, Kolodgie FD, Farb A, Lafont A: Drug eluting stents: Are human and animal studies comparable? Heart 2003, 89:127–132.CrossRefGoogle Scholar
  7. 6.
    Mehran R, Dangas G, Abizaid AS, et al.: Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 1999, 100:1872–1878.PubMedCrossRefGoogle Scholar
  8. 7.
    Waksman R, White RL, Chan RC, et al.: Intracoronary gamma-radiation therapy after angioplasty inhibits recurrence in patients with in-stent restenosis. Circulation 2000, 101:2165–2171.PubMedCrossRefGoogle Scholar
  9. 8.
    Waksman R, Rainer AE, Yeung AC, et al.: Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomized controlled trial. Lancet 2002, 359:551–557.PubMedCrossRefGoogle Scholar
  10. 9.
    Teirstein PS: Living the dream of no restenosis. Circulation 2001, 104:1996–1998.PubMedCrossRefGoogle Scholar
  11. 10.
    Lefkovits J, Topol EJ: Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention. Prog Cardiovasc Dis 1997, 40:141–158.PubMedCrossRefGoogle Scholar
  12. 11.
    Drachman DE, Edelman ER, Seifert P, et al.: Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. J Am Coll Cardiol 2000, 36:2325–2332.PubMedCrossRefGoogle Scholar
  13. 12.
    Van Beusekom HM, Schwartz RS, van der Giessen WJ: Synthetic polymers. Semin Interv Cardiol 1998, 3:145–148.PubMedGoogle Scholar
  14. 13.
    Suzuki T, Kopia G, Hayashi S, et al.: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 2001, 104:1188–1193.PubMedCrossRefGoogle Scholar
  15. 14.
    Heldman AW, Cheng L, Jenkins GM, et al.: Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001, 103:2289–2295.PubMedCrossRefGoogle Scholar
  16. 15.
    Sousa JE, Cosat MA, Abizaid AC, et al.: Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001, 104:2007–2011.PubMedCrossRefGoogle Scholar
  17. 16.
    Morice MA, Serruys PW, Sousa JE, et al.: A randomised comparison of a sirolimus-eluting stent with a standard stent for coronary revascularisation. N Engl J Med 2002, 346:1773–1780.PubMedCrossRefGoogle Scholar
  18. 17.
    Grube E, Silber S, Hauptmann K, et al.: TAXUS I prospective, randomized, double-blind comparison of NIRx™ stents coated with paclitaxel in a polymer carrier in de novo coronary lesions compared with uncoated controls. Circulation 2001, 104:11–463.CrossRefGoogle Scholar
  19. 18.
    Gershlick A, Descheerder I, Chevalier B: Local drug delivery to inhibit coronary artery stenosis. Data from ELUTES (evaluation of paclitaxel eluting stent) clinical trial. Circulation 2001, 104:11–416.Google Scholar
  20. 19.
    Honda Y, Grube E, de la Fuente LM, et al.: Novel drug delivery stent: intravascular ultrasound observations from the first human experience with the QP2-eluting polymer stent system. Circulation 2001, 104:380–383.PubMedCrossRefGoogle Scholar
  21. 20.
    Lustro F, Stankovic G, Di Mario C, et al.: First clinical experience with a paclitaxel derivate-eluting polymer stent system implantation for in-stent restenosis: immediate and long-term clinical and angiographic outcome. Circulation 2002, 105:1883–1886.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Anoop Chauhan
  • Ranjit S. More

There are no affiliations available

Personalised recommendations